Month: March 2025
Result Announced (Test Conducted by HEC/ETC)
Disclaimer
The completion of screening tests conducted by HEC/ETC and the marks obtained by candidates do not ensure employment with DRAP. Final selection will consider on the verification of candidate’s eligibility, which includes the submission of HEC-attested educational degrees and certificates, valid experience certificates, domicile certificate, CNIC and successful completion of a departmental interview conducted by the relevant Interview Committee. Furthermore, appointments to the positions of Deputy Directors (RO-13) and Directors (RO-15) will be subject to the decision of ongoing court case in the Honorable Baluchistan High Court.
1. Assistant Director – Budget & Accounts / Costing & Pricing
2. Assistant Director – Management Information Services
3. Assistant Director – Technical (Bio-Medical)
4. Assistant Director – Technical (Bio-technologist)
5. Assistant Director – Technical (Chemist)
6. Assistant Director – Technical (Microbiologist)
7. Assistant Director – Legal Affairs
8. Assistant Director – Technical
9. Deputy Directors – Technical
10. Directors – Admin, HR & Logistics / Budget Accounts & Costing Pricing / Legal Affairs / Technical
Recall Alert: SUBSTANDARD PRODUCTS DECLARED BY PROVINCIAL DRUG TESTING LABORATORIES.
Recall Alert
| DRAP Alert No | No I/S/03-25-28 |
| Action Date | 12th March, 2025. |
| Target Audience | – National Regulatory Field Force. – Pharmacists and Chemists in Distribution, Pharmacies and Medical Stores – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public |
| Problem / Issue | Directorate of Drug Control (DDC) Punjab has informed Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been reported as ‘Substandard’. |
Therapeutic Goods (s) Affected: –
| Product Names | Composition | Batch Details | Manufactured by |
|---|---|---|---|
Syrup Divanza 120ml Reg. No. 096103 | Each 5ml contains: Sodium Valproate eq. to Valproic acid …..250mg | 021 | M/s. Hiranis Pharmaceuticals (Pvt.) Ltd. E-145-149, North Western Industrial Zone, Port Qasim, Karachi. |
| Tablet Mebrosil Antacid Reg. No. 007733 | Each tablet contains: Magnesium Trisilicate…500mg, Aluminium Hydroxide…250mg | 8576 | M/s. Jawa Pharmaceuticals (Pvt) Ltd, 112/10 Quaid-e-Azam Industrial Area, Kot-Lakhpat, Lahore. |
| Capsule Lanroz 30mg Reg. No. 047803 | Each capsule contains: Lansoprazole….30mg | C-032 | M/s. Hisun Pharmaceuticals Indsutries, 37-A, R-2, Industrial Estate, Gadoon-Pakistan. |
| Sterile Disposable Fresline Reg. No. MDIR-0001626 | (Tubing Sets for Hemodialysis) | 2401151264 | Manufactured by: M/s Vital Healthcare SDN. BHD., Lot 3, Jalan sultan Mohamed 3, Bandar Sultan Sulaiman, 42000 Pelabuhan klang, Selangor Darul Ehsan, Malaysia. Imported by: Fresenius Medical Care Pakistan (Pvt.) Ltd., TAMC, First Floor, 27-C III, M.M Alam Road, Gulberg III, Lahore. |
| Tablet AMLOShine 5mg Reg. No. 062420 | Each tablet contains: Amlodipine as besylate…5mg | 6752 | M/s Sunshine Pharmaceuticals, Khan payara, near Saim Nala, Emanabad Road, Emanabad, Gujranwala |
| AME-CLOP Injection Reg. No. 048388 | Each 2ml contains: Metoclopramide HCL….10mg | MC-120 | M/s Ameer Pharma (Pvt) Ltd., 23-Km, Sheikhupura Road, Lahore. |
| Injection Anacobin 500µg Reg. No. 047494 | (Mecobalamin 500 µg/ml, 1ml) | AF133 | M/s Epharm Laboratories, A-40, Road No. 1, S.I.T.E., Super Highway, Industrial Area, North Karachi. |
| Tablet Normax 5mg Reg. No. 062644 | Each tablet contains: Amlodipine as besylate…..5mg | 327 | M/s Murfy Pharmaceuticals (Pvt) Ltd., 8-Km Raiwind Road, Lahore. |
| Risk Statement: | The use of substandard products can result in therapy failure, increasing the risk of complications, particularly in vulnerable groups such as immunocompromised individuals, as well as pediatric and geriatric population. |
| Action Initiated | – The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s). |
| Advice for Healthcare Professionals | DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP. |
| Advice for Consumers | -Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist. |
Minutes of 5th Meeting of the Pharmacovigilance Risk Assessment Expert Committee (PRAEC) held on January 2, 2025
Rapid Alert: CRACKDOWN AGAINST FALSIFIED / SPURIOUS DRUGS
Rapid Alert
| DRAP Alert No | No I/S/03-25-28 |
| Action Date | 5th March, 2025 |
| Target Audience | 1. Regulatory Field Force of DRAP and Provincial Drug Control departments. 2. Healthcare Professionals 3. Pharmacies and medical stores |
| Problem Statement | Directorate of Drug Control Punjab (DDCP) has informed the Drug Regulatory Authority of Pakistan that the samples of the below mentioned products have been declared ‘Spurious’. |
The product identification details are as under: –
Therapeutic Good Affected:-
| Product | Batch No* | Mfg Date | Exp. Date | Manufacturer Name (as per label) | Remarks |
| Syrup Carenol 60mL Each 5ml contains: Ammonium chloride 125mg, Sodium Citrate 55mg, Chlorpheniramine maleate 2.5mg Reg. No. 026907 | CL-036 | Purported to be manufactured by Well Care Pharmaceuticals, A/7, P.S.I.E. Sargodha-Pakistan. | ‘Spurious’ as per Drugs Act 1976, section 3(z-b) (i) and ‘Misbranded’ as per section 39(s)(vi). | ||
| Powder for Inj. 2Sum 2g Sterile powder of Cefoperazone sodium eq. to Cefoperazone 1g, Sterile powder for sulbactam sodium eq. to Sulbactum 1g per vial Reg. No. 071447 | APK072 | Purported to be manufactured by Healthtek (Pvt) Ltd, Plot No. 14, Sector 19, Korangi Industrial Area Karachi -Pakistan. | Spurious’ as per Drugs Act 1976, section 3(z-b) (i) & (ii) and ‘Adulterated’ as per section 3(s)(iv) and ‘Substandard’ on the basis of Sterility. |
| Risk Statement | Falsified products having no active ingredient or identification of manufacturer pose a great risk to the health of patient and can cause adverse drug reactions or may lead to therapy failure that can result in fatal consequences. |
| Action Initiated | The Regulatory Field Force has been directed to conduct surveillance activities to confiscate the abovementioned Un-Registered/falsified products. All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock, and information related to the suppliers of such products should be provided to the Regulatory field force (DRAP, Provincial Drug Control Departments) to ensure the removal of these product from the circulation. |
| Advice for Healthcare Professionals | DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link. |
| Advice for Consumers | Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt. |
Recall Alert: SUBSTANDARD PRODUCTS DECLARED BY PROVINCIAL DRUG TESTING LABORATORIES.
Recall Alert
| DRAP Alert No | No I/S/03-25-26 |
| Action Date | 4th March, 2025. |
| Target Audience | – National Regulatory Field Force. – Pharmacists and Chemists in Distribution, Pharmacies and Medical Stores – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public |
| Problem / Issue | Directorate of Drugs Control (DDC) Punjab and Senior Drug Inspector ICT Islamabad has informed DRAP that samples below product has been reported substandard due to presence of impurities by Drug Testing Laboratory (DTL) Lahore and Rawalpindi: |
Therapeutic Goods (s) Affected: –
| Product Names | Composition | Batch Details | Manufactured by |
|---|---|---|---|
Ame-Pin injection 2ml | Tramadol HCl 100mg | TD-038 | Ameer Pharma (Pvt.) Ltd., 23 KM, Sheikhupura road, Lahore |
| Aqua-P Injection | Sterile Water For Injection | P-665 | Ipram International, Plot No. 26, SS-3, NIZ, Rawat Islamabad |
| Flagyl Infusion | Metronidazole 500mg | AD460 | Sanofi-Aventis Pakistan Ltd., Plot No. 23, Sector 22, KIA, Karachi |
| Metroin Infusion | Metronidazole 500mg | MT24-103 | Saturn Pharmaceuticals, 23Km,Thokar-Raiwind Rd, Lahore |
| Euro-Flow Cannula | IV Cannula | 24/87 | Euromed for Medical Industries SAE Cairo Egypt |
| Rudazole Injection | Metronidazole 500mg | RD-044 | Rukha Pharmaceutical & Laboratories, 537-D&E Sundar Industrial Estate Lahore |
| Safemed Injection | Metronidazole 500mg | S-699 | Ahad Intl., Pharmaceutical, 13KM Gomal Uni, Multan Road, DI Khan |
| Pulmowell 120ml syrup | (Ammonium Chloride 30mg, Liquorice Ext. 50mg, Aniseed Oil 2.6ml) | PLW-001 | Vital Phyto Parma (Pvt.) Ltd., 7 KM from GT Road, Sohawa Chakwal Road, Rawalpindi |
| Risk Statement: | The use of substandard products can result in therapy failure, increasing the risk of complications, particularly in vulnerable groups such as immunocompromised individuals, as well as pediatric and geriatric population. |
| Action Initiated | – The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s). |
| Advice for Healthcare Professionals | DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP. |
| Advice for Consumers | -Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist. |
Recall Alert: Substandard Products Declared By Provincial Drug Testing Laboratories:
Recall Alert
| DRAP Alert No | No I/S/03-25-27 |
| Action Date | 4th March, 2025. |
| Target Audience | – National Regulatory Field Force. – Pharmacists and Chemists in Distribution, Pharmacies and Medical Stores – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public |
| Problem / Issue | Directorate of Drug Control (DDC) Punjab has informed Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been reported as ‘Substandard’. |
Therapeutic Goods (s) Affected: –
| Product Names | Composition | Batch Details | Manufactured by |
|---|---|---|---|
| Aqua-P Injection | Sterile Water For Injection | P-665 | Ipram International, Plot No. 26, SS-3, NIZ, Rawat Islamabad |
| Injection Neocobal 1 ml Reg. No. 071447 | Mecobalamin 0.5mg/ml | S-2216 | M/s. Pulse Pharmaceuticals (Pvt.) Ltd. Sua Aasil, Raiwind Road, Lahore – Pakistan |
| Syrup Antimin 60ml Reg. No. 025951 | Each 5ml contains: Loratadine …..5mg | 063 | M/s. Shaigan Pharmaceuticals (Pvt) Ltd, 14-Km, Adyala Road, Rawalpindi – Pakistan |
| Injection Cara-Lac Reg. No. 054997 | Ketorolac Tromethamine 30mg/mL | 24J013 | M/s. Caraway Pharmaceuticals, Plot 12, St. N-3, National Industrial Zone (RCCI), Rawat, Islamabad. |
| Risk Statement: | The use of substandard products can result in therapy failure, increasing the risk of complications, particularly in vulnerable groups such as immunocompromised individuals, as well as pediatric and geriatric population. |
| Action Initiated | – The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s). |
| Advice for Healthcare Professionals | DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP. |
| Advice for Consumers | -Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist. |